Beiersdorf

Inline skates for a limping Elephant?

22/02/21 -"We have added the higher CARE expenses to our model, which will be partly cushioned by higher profitability. This negatively effects primarily our EPS in the estimate years, whereas our DCF model is ..."

PDF page sample
Pages
56
Language
English
Published on
22/02/21
Download
You may also be interested by these reports :
24/10/25
Beiersdorf reported Q3 25 sales slightly below consensus on organic growth, driven by continued strength in derma cosmetics. Nivea remained affected ...
23/10/25
Unilever reported stronger-than-expected results, with underlying sales growth at 3.9%, surpassing the forecasted 3.7% by 20bps. This performance was ...
21/10/25
L’Oréal’s Q3 25 sales came in slightly below consensus, with all divisions softer than expected except for Professional Products. Premium haircare ...
23/09/25
With rates down, holding ASML clearly makes more sense than Reckitt. However, the 15% gain of ASML (+€41bn to €311bn) over the week to 19-09 led us ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO